Examkin

Soru

Zorluk: Çok zorStatistical Inference and Hypothesis Testing

A pharmaceutical company conducts a randomized, double-blind non-inferiority trial comparing a novel once-daily oral antibiotic to the standard thrice-daily intravenous therapy for the treatment of uncomplicated pyelonephritis. The primary endpoint is the clinical cure rate at 1414 days. The investigators establish a predefined non-inferiority margin (Δ\Delta) of −6.0%-6.0\%, meaning the new oral antibiotic will be deemed non-inferior if its cure rate is no more than 6.06.0 absolute percentage points lower than the standard therapy.

Upon study completion, the absolute difference in clinical cure rates (novel antibiotic minus standard therapy) is calculated to be −3.0%-3.0\%. The 95%95\% confidence interval (CI) for this difference is [−5.2%,−0.8%][-5.2\%, -0.8\%], with a one-sided pp-value of 0.010.01 for non-inferiority.

Based on the information above, which of the following is the most accurate statistical interpretation of these trial results?

  1. The novel antibiotic is non-inferior to the standard therapy, but it is statistically less effective.Cevap
  2. B
    The novel antibiotic failed to demonstrate non-inferiority because the confidence interval does not cross 0%0\%.
  3. C
    The novel antibiotic is considered superior to the standard therapy because the associated pp-value is less than 0.050.05.
  4. D
    The trial results are invalid due to unmeasured confounding, as the treatment effect estimate remains entirely negative.
  5. E
    The positive predictive value of achieving a clinical cure with the novel antibiotic is inherently reduced by the −6.0%-6.0\% margin.

Cevap

The novel antibiotic is non-inferior to the standard therapy, but it is statistically less effective.
In a non-inferiority trial, a new treatment is considered non-inferior if the lower bound of the 95%95\% confidence interval for the treatment difference sits above the predefined negative non-inferiority margin (−Δ-\Delta). Here, the lower bound is −5.2%-5.2\%, which is greater than the −6.0%-6.0\% margin, confirming non-inferiority. However, because the entire confidence interval [−5.2%,−0.8%][-5.2\%, -0.8\%] falls below 0%0\%, the novel antibiotic is statistically significantly less effective than the standard therapy. This often occurs when a drug trades a small, acceptable loss in efficacy for other clinical benefits, such as a more convenient dosing route.

Adım Adım Çözüm

1
Evaluate the confidence interval against the non-inferiority margin.
The lower bound of the 95%95\% CI is −5.2%-5.2\%. This is greater (closer to zero) than the non-inferiority margin of −6.0%-6.0\%.
To prove non-inferiority, the worst-case scenario (lower bound of the CI) must not cross the predefined unacceptable difference (Δ\Delta).
2
Evaluate the confidence interval against the line of no difference (null hypothesis for superiority).
The upper bound of the 95%95\% CI is −0.8%-0.8\%, which is strictly less than 0%0\%.
If a confidence interval for an absolute difference does not cross 0%0\%, the difference is statistically significant. Since it is entirely negative, the novel drug is statistically less effective.
3
Synthesize the findings to form a complete clinical and statistical conclusion.
The novel antibiotic meets the criteria for non-inferiority but is simultaneously statistically inferior in efficacy compared to the standard therapy.
This is a common and valid outcome in non-inferiority trials, often accepted because the new drug provides auxiliary benefits (e.g., oral administration vs. intravenous).

Anahtar Kavram

Confidence interval interpretation in non-inferiority trials
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Statistical Inference and Hypothesis Testing

Bu konudan daha fazla soru